Carl Baumeister
YOU?
Author Swipe
View article: Changes in Plasma Aβ42/40 Ratio and p-Tau181 in Amyloid-Positive Patients Treated with Sirolimus
Changes in Plasma Aβ42/40 Ratio and p-Tau181 in Amyloid-Positive Patients Treated with Sirolimus Open
Alzheimer’s disease (AD) is characterized by amyloid-beta (Aβ) accumulation and tau protein pathology. The Aβ42/40 ratio serves as a key biomarker of amyloid burden, with lower ratios associated with disease progression. Similarly, elevate…